Meeder Advisory Services Inc. Acquires 1,516 Shares of Moderna, Inc. (NASDAQ:MRNA)

Meeder Advisory Services Inc. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 78.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,447 shares of the company’s stock after purchasing an additional 1,516 shares during the period. Meeder Advisory Services Inc.’s holdings in Moderna were worth $409,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Cedar Wealth Management LLC raised its stake in Moderna by 45.0% in the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its holdings in shares of Moderna by 1.7% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after acquiring an additional 93 shares during the period. CVA Family Office LLC raised its position in shares of Moderna by 21.6% in the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after acquiring an additional 96 shares in the last quarter. Claro Advisors LLC lifted its stake in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after purchasing an additional 108 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its position in Moderna by 32.3% during the fourth quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after purchasing an additional 116 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In other news, President Stephen Hoge sold 15,000 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the sale, the president now directly owns 1,442,089 shares of the company’s stock, valued at approximately $174,665,819.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the sale, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total transaction of $1,816,800.00. Following the transaction, the president now owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 93,158 shares of company stock worth $11,167,312. 15.70% of the stock is owned by company insiders.

Moderna Stock Down 2.0 %

Shares of MRNA opened at $68.28 on Monday. The stock’s 50-day moving average price is $95.06 and its 200-day moving average price is $111.89. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $26.17 billion, a price-to-earnings ratio of -4.36 and a beta of 1.67. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($3.33) EPS for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The business had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. During the same quarter last year, the company earned ($3.62) EPS. The business’s revenue was down 29.9% on a year-over-year basis. On average, sell-side analysts predict that Moderna, Inc. will post -9.52 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have commented on MRNA shares. Royal Bank of Canada decreased their price target on shares of Moderna from $90.00 to $75.00 and set a “sector perform” rating for the company in a research report on Friday. Piper Sandler lowered their price target on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a report on Friday. Jefferies Financial Group downgraded shares of Moderna from a “buy” rating to a “hold” rating and cut their price objective for the company from $120.00 to $65.00 in a report on Friday. Barclays decreased their price objective on shares of Moderna from $168.00 to $155.00 and set an “overweight” rating for the company in a research report on Friday, August 2nd. Finally, The Goldman Sachs Group cut their price target on shares of Moderna from $204.00 to $178.00 and set a “buy” rating on the stock in a research note on Friday, August 2nd. One research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna has an average rating of “Hold” and a consensus target price of $108.53.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.